Vaxart, Inc. Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Assets, Prepaid Expense and Other Assets
Vaxart, Inc. (VXRT) had Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Assets, Prepaid Expense and Other Assets of $436.00 thousand as of 2018-12-31, per its 10-K filed 2021-02-25.
Discontinued › Notes › Business Combinations › Business Combination, Asset Acquisition, Transaction between Entities under Common Control, and Joint Venture Formation › Business Combination, Recognized Asset Acquired to Liability Assumed, Excess (Less), and Goodwill › Business Combination, Recognized Asset Acquired to Liability Assumed, Excess (Less) › Business Combination, Recognized Asset Acquired, Asset › Business Combination, Recognized Asset Acquired, Asset, Current
us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets · last filed 2021-02-25
- 2018-12-31: Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Assets, Prepaid Expense and Other Assets $436.00K.
- 2018-09-30: Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Assets, Prepaid Expense and Other Assets $436.00K.
- 2018-06-30: Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Assets, Prepaid Expense and Other Assets $436.00K.
- 2018-02-13: Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Assets, Prepaid Expense and Other Assets $446.00K.
| Period end | Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Assets, Prepaid Expense and Other Assets |
|---|---|
| 2018-12-31 | $436.00K 10-K · filed 2021-02-25 |
| 2018-09-30 | $436.00K 10-Q · filed 2018-11-13 |
| 2018-06-30 | $436.00K 10-Q · filed 2018-08-10 |
| 2018-02-13 | $446.00K 10-Q · filed 2018-05-15 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Kalaris Therapeutics, Inc. (KLRS) | United States | $0.073B | -2.19 |
| Atara Biotherapeutics, Inc. (ATRA) | United States | $0.086B | -6.48 |
| Pelthos Therapeutics Inc. (PTHS) | United States | $0.086B | -1.20 |
| CHAMPIONS ONCOLOGY, INC. (CSBR) | United States | $0.070B | -68.02 |
| COGNITION THERAPEUTICS INC (CGTX) | United States | $0.090B | -6.52 |
| BioStem Technologies, Inc. (BSEM) | United States | $0.069B | |
| Eloxx Pharmaceuticals, Inc. (ELOX) | United States | $0.065B | |
| MiNK Therapeutics, Inc. (INKT) | United States | $0.063B | -5.37 |
| Cardiff Oncology, Inc. (CRDF) | United States | $0.101B | -2.22 |
| EXOZYMES INC. (EXOZ) | United States | $0.058B |